Abstract
IntroductionBenralizumab is an anti-IL5R monoclonal antibody licensed for patients with severe eosinophilic asthma (SEA). Phase 3 clinical trials demonstrated significant reductions in exacerbation rates and in maintenance oral corticosteroid (mOCS)...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
